Primary endpoint: To prospectively enumerate CTCs using Nanovelcro technology in patients undergoing specific forms of therapy for prostate cancer. This will allow us to monitor patients responses to these treatments using CTC number as a biomarker. This pilot study will establish the threshold CTC number and trends relative to the natural history of prostate cancer in different stages of the disease and using specific modes of therapy. This data will open the door for future large-scale studies that can establish CTC number as a viable biomarker to monitor response to treatment in prostate cancer patients in these disease spaces. Secondary endpoints: 1. To test the applicability of advanced biological characterization technologies to circulating tumor cells including: o Next generation sequencing o Single cell sequencing o Fluorescence/mQDOT analysis o CTC culture 2. To pilot a comparison of CTCs and primary and metastatic tumors using the above mentioned technologies. 3. To retrospectively explore the potential relationships between molecular alternations and clinical outcomes relative to therapeutic response and disease progression using this data (if possible).